A Glimpse Into The Expert Outlook On Autolus Therapeutics Through 5 Analysts
Portfolio Pulse from Benzinga Insights
Analysts' ratings for Autolus Therapeutics (NASDAQ:AUTL) over the last quarter show a range of sentiments from bullish to bearish. The average 12-month price target is $9.4, with a high of $11.00 and a low of $9.00. The company's market capitalization, revenue growth, and debt management are strong, but it faces challenges with net margin, ROE, and ROA.
June 17, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts' ratings for Autolus Therapeutics (NASDAQ:AUTL) show mixed sentiments, with a 12-month price target averaging $9.4. The company has strong market capitalization and revenue growth but faces challenges with net margin, ROE, and ROA.
The mixed analyst ratings and stable price targets suggest a neutral short-term impact on AUTL's stock price. The company's strong market cap and revenue growth are positive, but challenges with net margin, ROE, and ROA balance out the outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100